Venus Medtech (02500.HK) Issues Announcement Pursuant to HKEX Request, Responding to Rumors of Overseas Patent Litigation Involving Its Subsidiary

NewTimeSpace · 2026/01/20 13:07 · By Jiayi Sun

Venus Medtech (02500.HK) released an announcement confirming that its wholly-owned subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P. have filed a patent infringement lawsuit against Edwards Lifesciences Corp. and other parties with the United States District Court for the District of Delaware. The company stated that following reasonable inquiries, there is no inside information that needs to be disclosed pursuant to the Listing Rules.

Venus Medtech (Hangzhou) Inc. (02500.HK) issued an announcement pursuant to a request from the Stock Exchange of Hong Kong Limited (HKEX), responding to recent media reports regarding the patent infringement lawsuit filed in the United States by its subsidiary Cardiovalve Ltd. and joint venture MTH IP, L.P.

The announcement confirmed that Cardiovalve Ltd. (the wholly-owned subsidiary of the company) and MTH IP, L.P. (the joint venture of the company) have instituted a patent infringement lawsuit against Edwards Lifesciences Corp. and Edwards Lifesciences LLC in the United States District Court for the District of Delaware.

The company stated that after making reasonable enquiries in the circumstances, it confirmed that it is not aware of any information that needs to be announced to avoid the creation of a false market in the company’s securities, nor is there any inside information required to be disclosed under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.

The company reminded shareholders and potential investors to exercise caution when dealing in the company’s shares.

Tags：

VENUS MEDTECH-B 02500.HK patent infringement lawsuit